Detalles de la búsqueda
1.
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
J Infect Dis
; 229(4): 1068-1076, 2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37673423
2.
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
J Infect Dis
; 227(2): 268-277, 2023 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35776140
3.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLoS Med
; 19(1): e1003865, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015777
4.
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
J Antimicrob Chemother
; 70(5): 1482-6, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25652748
5.
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Lancet Infect Dis
; 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38552653
6.
Vaccine value profile for Klebsiella pneumoniae.
Vaccine
; 2024 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38503661
7.
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
Front Immunol
; 14: 1215302, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37727795
8.
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
EBioMedicine
; 91: 104562, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37099841
9.
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Vaccine
; 41(50): 7573-7580, 2023 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37981473
10.
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
Trials
; 23(1): 513, 2022 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35725488
11.
Challenges in diagnosis, treatment and follow-up of patients presenting with central nervous system infections in a resource-limited setting.
Mcgill J Med
; 9(1): 39-48, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19529809
12.
First-line antiretroviral therapy in Africa--how evidence-base are our recommendations?
AIDS Rev
; 7(3): 148-54, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16302462
13.
Clinical presentation and aetiologies of acute or complicated headache among HIV-seropositive patients in a Ugandan clinic.
J Int AIDS Soc
; 12: 21, 2009 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-19765315
14.
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
Afr Health Sci
; 8(1): 8-12, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19357726
Resultados
1 -
14
de 14
1
Próxima >
>>